We sat down with Pfizer Inc.’s Worldwide President of R&D Mikael Dolsten on Feb. 13 at the BIO CEO conference in New York to drill down into some of the subjects covered in his fireside chat earlier that morning. Dolsten leads Pfizer’s small and large molecule R&D across all therapeutic areas as well as vaccines. He also co-chairs the company's Portfolio Strategy and Investment (PSI) Committee, which governs major pipeline investments and strategic R&D priorities. He joined Pfizer in 2009 from Wyeth where he was President of Wyeth Research.
Pfizer’s branded pharmaceutical business is showing signs of a robust turnaround after a string of recent disappointments in the clinic...